CL2014000988A1 - Compounds derived from (aryl or heteroaryl) cyclopropylamide, lsd1 inhibitors; procedure to prepare them; pharmaceutical composition that includes them; and method to treat or prevent cancer, a neurological disease, a viral infection and viral reactivation after latency. - Google Patents
Compounds derived from (aryl or heteroaryl) cyclopropylamide, lsd1 inhibitors; procedure to prepare them; pharmaceutical composition that includes them; and method to treat or prevent cancer, a neurological disease, a viral infection and viral reactivation after latency.Info
- Publication number
- CL2014000988A1 CL2014000988A1 CL2014000988A CL2014000988A CL2014000988A1 CL 2014000988 A1 CL2014000988 A1 CL 2014000988A1 CL 2014000988 A CL2014000988 A CL 2014000988A CL 2014000988 A CL2014000988 A CL 2014000988A CL 2014000988 A1 CL2014000988 A1 CL 2014000988A1
- Authority
- CL
- Chile
- Prior art keywords
- viral
- cyclopropylamide
- latency
- heteroaryl
- aryl
- Prior art date
Links
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 208000036142 Viral infection Diseases 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 230000007419 viral reactivation Effects 0.000 title 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382324 | 2011-10-20 | ||
| EP11323298 | 2011-10-27 | ||
| US201161558370P | 2011-11-10 | 2011-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000988A1 true CL2014000988A1 (en) | 2014-11-03 |
Family
ID=52002339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000988A CL2014000988A1 (en) | 2011-10-20 | 2014-04-17 | Compounds derived from (aryl or heteroaryl) cyclopropylamide, lsd1 inhibitors; procedure to prepare them; pharmaceutical composition that includes them; and method to treat or prevent cancer, a neurological disease, a viral infection and viral reactivation after latency. |
Country Status (1)
| Country | Link |
|---|---|
| CL (1) | CL2014000988A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10189802B2 (en) | 2008-11-07 | 2019-01-29 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US10695444B2 (en) | 2015-06-19 | 2020-06-30 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof |
| US10717737B2 (en) | 2014-02-13 | 2020-07-21 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US10723700B2 (en) | 2015-08-12 | 2020-07-28 | Incyte Corporation | Salts of an LSD1 inhibitor |
| US10968221B2 (en) | 2014-07-10 | 2021-04-06 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US11155532B2 (en) | 2014-02-13 | 2021-10-26 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US11401272B2 (en) | 2015-04-03 | 2022-08-02 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
| US11458158B2 (en) | 2011-10-27 | 2022-10-04 | Massachusetts Institute Of Technology | Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof |
-
2014
- 2014-04-17 CL CL2014000988A patent/CL2014000988A1/en unknown
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10189802B2 (en) | 2008-11-07 | 2019-01-29 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US11414393B2 (en) | 2008-11-07 | 2022-08-16 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US11458158B2 (en) | 2011-10-27 | 2022-10-04 | Massachusetts Institute Of Technology | Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof |
| US11155532B2 (en) | 2014-02-13 | 2021-10-26 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US11247992B2 (en) | 2014-02-13 | 2022-02-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US10717737B2 (en) | 2014-02-13 | 2020-07-21 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US10968221B2 (en) | 2014-07-10 | 2021-04-06 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US11401272B2 (en) | 2015-04-03 | 2022-08-02 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
| US10695444B2 (en) | 2015-06-19 | 2020-06-30 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof |
| US10723700B2 (en) | 2015-08-12 | 2020-07-28 | Incyte Corporation | Salts of an LSD1 inhibitor |
| US11498900B2 (en) | 2015-08-12 | 2022-11-15 | Incyte Corporation | Salts of an LSD1 inhibitor |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US11512064B2 (en) | 2018-08-31 | 2022-11-29 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000988A1 (en) | Compounds derived from (aryl or heteroaryl) cyclopropylamide, lsd1 inhibitors; procedure to prepare them; pharmaceutical composition that includes them; and method to treat or prevent cancer, a neurological disease, a viral infection and viral reactivation after latency. | |
| CL2014003035A1 (en) | Compounds derived from diazabicyclooctane, beta-lactamase inhibitors; pharmaceutical composition that includes them; process to prepare them; and method to treat a bacterial infection. | |
| CL2013003257A1 (en) | Compounds derived from pyrrolidinyl- (urea, thiourea or guanidine) trka kinase inhibitors; process to prepare them; pharmaceutical composition that includes them; and its use to treat pain, cancer, inflammation, neurodegenerative disease or an infection of trypanosoma cruzi. | |
| EA201500207A1 (en) | HETEROAROMATIC COMPOUNDS AS VTK INHIBITORS | |
| CL2014001641A1 (en) | Compounds derived from substituted nucleosides, nucleotides and analogs thereof; pharmaceutical composition; and use to improve or treat a viral infection. | |
| EA201590975A1 (en) | PRMT5 INHIBITORS AND THEIR APPLICATION | |
| BR112015022191A8 (en) | heteroaryl compounds and uses thereof | |
| EA201591166A1 (en) | AUTOTAXIN INHIBITORS | |
| BR112015011112A2 (en) | oligomeric compound, oligomer, pharmaceutical composition, use of the oligomeric compound, method of synthesis of an oligomeric compound and method of treating a disease. | |
| CL2015000925A1 (en) | Compounds derived from nitrogen heterocycles; pharmaceutical composition; a method to treat viral infections caused by respiratory syncytial virus (vsr) | |
| DK3750545T3 (en) | PHOSPHOLIPIDE THERA ANALOGUES AS CANCER TARGETED DRUG CARRIERS | |
| UY33370A (en) | Pharmaceutical compositions comprising a DPP4 and pioglitazone inhibitor drug, preparation and use procedures | |
| CL2014000245A1 (en) | Compounds derived from nitrogen heterocycles, inhibitors of influenza virus replication; Preparation method; pharmaceutical composition; method to inhibit influenza virus replication in a biological sample or a patient. | |
| CL2013002612A1 (en) | Compounds derived from c4-monomethyl triterpenoids; pharmaceutical composition that includes them; and method to treat or prevent a disease or disorder. | |
| CO6741228A2 (en) | Neprilysin Inhibitors | |
| BR112014008126A2 (en) | compound, method for treatment, pharmaceutical composition, use of a compound and invention | |
| BR112015001101A2 (en) | crystalline forms of a prolyl hydroxylase inhibitor | |
| BR112015009636A8 (en) | compound, methods for treating an infected host, methods for preventing an infection, methods for reducing the biological activity of an infection, and using a compound | |
| EA201591531A1 (en) | ARGININMETILTRANSFERASE INHIBITORS AND THEIR APPLICATIONS | |
| BRPI0914927A2 (en) | compound, pharmaceutical composition, methods for inhibiting fak function and cancer treatment, use of a compound, and process for preparing a compound | |
| BR112015002541A2 (en) | compound, pharmaceutical composition, use of a compound, and method for treating hcv in a patient. | |
| CL2014001110A1 (en) | Compounds derived from substituted piperazin-pyridin-biphenyl-imidazole-pyrrolidines, hepatitis C virus replication inhibitors (hcv); pharmaceutical composition that includes them; process to prepare a compound; method to treat an hcv virus infection; and use to treat an hcv virus infection. | |
| EA201400412A1 (en) | SUBSTITUTED BENZILINDAZOLES FOR USE AS BUB1 INHIBITORS KINAZES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | |
| EA201790661A3 (en) | HEPATITIS C VIRUS INHIBITORS | |
| BR112014009114A2 (en) | compounds, pharmaceutical compositions, treatment methods, uses of a compound and polymorph preparation process |